|
Takeda Pharmaceuticals, the manufacturer of the Type 2 diabetes medication Actos, is being accused of hiding important information that could have delayed or prevented the drug’s release. Since its release in 2008, Actos has been linked to an increased risk of developing bladder cancer. The accusations against Takeda claim that the company knew about this and many other dangers during the drug’s testing phases, but failed to accurately report the what they discovered in order to preserve Actos’s reputation as a safe alternative to other diabetes medications. Since its release, Actos has gained a majority of the diabetes drug market due to how it was advertised as a safe alternative to a major competitor that was shown to cause heart failure. Actos is known to cause similar heart problems, but many cases of such heart concerns were allegedly not deemed serious enough to report to the FDA. Additionally, Takeda is facing accusations that from an internal database of 100 instances of bladder cancer, it only reported 72 to the FDA. The accusations against Actos’s manufacturer assert that evidence of cancer was found during initial animal testing and later confirmed during what is called Phase III testing. Takeda is accused of hiding this information, but spokespeople for the company uphold that it ““complies with all laws and regulations regarding the reporting of adverse events.” Whether or not these allegations are true, Actos is still a dangerous drug. If you have been diagnosed with bladder cancer after taking Actos as directed, the Actos lawsuit attorneys Williams Kherkher can help you hold the drug’s negligent manufacturer accountable for its actions. They can help you seek compensation for your medical costs and other related expenses.
Related Articles -
Actos lawsuit attorney, Actos, bladder cancer, Takeda,
|
